Walton, Russell T.
Hsu, Jonathan Y.
Joung, J. Keith
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R00-CA218870, P01-HL142494, R35 GM118158, RM1 HG009490, P01-HL142494, R35 GM118158, RM1 HG009490, R35 GM118158)
Article History
Received: 26 August 2020
Accepted: 18 November 2020
First Online: 5 February 2021
Competing interests
: All authors are inventors on patent applications filed by Partners HealthCare that describe gene-editing and/or epigenome-editing technologies; R.T.W. and B.P.K. are inventors on a patent application related to the HT-PAMDA method. B.P.K. is an advisor to Acrigen Biosciences and consults for Avectas Inc. and ElevateBio. J.K.J. has financial interests in Beam Therapeutics, Chroma Medicine (formerly known as YKY, Inc.), Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, SeQure Dx, Inc., Transposagen Biopharmaceuticals, and Verve Therapeutics (formerly known as Endcadia). J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.